Aktienanalyse zu Immunocore Holdings PLC (IMCR)IMCRImmunocore Holdings PLC

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Immunocore Holdings PLC is a good buy right now due to its current price of $36.62, which is significantly below the analyst price target of $50 from JPMorgan. The company has shown a revenue growth of 16% year-over-year, with $223 million in net revenue for the first half of 2026, indicating strong market performance. However, the main risk is the negative earnings per share of -0.02 reported for Q2 2026, which reflects ongoing financial challenges.